RA Capital's sustained and accelerating accumulation at ~$9-10/share suggests a near-term catalyst (e.g., clinical data, partnership, or financing). Traders should monitor for upcoming press releases or SEC filings (e.g., 8-K, SC 13D amendment) and consider building a long position with a stop below the cluster's average cost (~$9.30).
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 24 $10.03entry
- T+1 · 4mo ago +2.89%α +2.87% · $10.32
- T+5 · 4mo ago +3.99%α +3.61% · $10.43
- T+20 · 3mo ago +8.97%α +5.35% · $10.93
- T+60 · 29d ago −41.28%α −45.00% · $5.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
RA Capital Management, a 10% owner and director, purchased a total of ~281K shares of Artiva Biotherapeutics for ~$2.58M across three open-market buys from July 14-21, 2026. This follows a separate cluster of RA Capital purchases totaling ~$2.58M in the prior week (July 21-23), bringing the combined insider buying to ~$5.2M over a ~10-day period. At a $248M market cap, this represents ~2.1% of the company, a highly material signal from a sophisticated healthcare investor with board representation, indicating strong conviction ahead of a potential catalyst.
Key Financial Metrics
Key Facts
- RA Capital Management (Director, 10% Owner) purchased ~281K shares for ~$2.58M across three open-market buys from July 14-21, 2026.
- Combined with a separate cluster of RA Capital purchases from July 21-23 (~$2.58M), total insider buying over ~10 days is ~$5.2M.
- Total insider buying represents ~2.1% of ARTV's $248M market cap, exceeding the >2% threshold for highly material insider activity.
- RA Capital is a sophisticated healthcare-focused investment firm with board representation, amplifying the signal's credibility.
Financial Impact
Insider purchases totaling ~$5.2M (~2.1% of market cap) from a 10% owner/director over ~10 days
Risk Factors
- Biotech clinical-stage risk: any negative data readout or regulatory setback could reverse the signal.
- Insider buying by a single large holder may reflect portfolio allocation rather than a near-term catalyst.
- High concentration of buying from one entity reduces diversification of the signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000791 |
Track record
33 reports on ARTV
10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers